verapamil has been researched along with Weight Loss in 4 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 8.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 4.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| " Administration of verapamil, an L-type calcium channel blocker which was effective for hypertension in SHRSP rats, prevented the decrease in plasma protein expression." | 3.74 | Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats. ( Goto, H; Hayashi, K; Kiga, C; Saiki, I; Sakurai, H; Shimada, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eissa, LD | 1 |
| Ghobashy, WA | 1 |
| El-Azab, MF | 1 |
| Kiga, C | 1 |
| Sakurai, H | 1 |
| Goto, H | 1 |
| Hayashi, K | 1 |
| Shimada, Y | 1 |
| Saiki, I | 1 |
| Freeman, L | 1 |
| Mazur, LJ | 1 |
| Nakano, GI | 1 |
| Katoh, H | 1 |
| Ikeda, H | 1 |
| Sakamoto, K | 1 |
| Nagamachi, Y | 1 |
4 other studies available for verapamil and Weight Loss
| Article | Year |
|---|---|
Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury.
Topics: Angiogenesis Inhibitors; Animals; Blood Glucose; Calcium Channel Blockers; Cell Cycle Proteins; Diab | 2021 |
Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats.
Topics: Animals; Biomarkers; Blood Proteins; Haptoglobins; Hypertension; Male; Proteomics; Rats; Rats, Inbre | 2008 |
Verapamil therapy for persistent antral spasms in a child.
Topics: Abdominal Pain; Calcium Channel Blockers; Child; Esophagitis; Gastrointestinal Motility; Humans; Mal | 1996 |
[Experimental study on combination chemotherapy of UFT and calcium antagonist in gastric cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Drug Screening Assays, Antit | 1989 |